Current clinical trials

Current clinical trials

Bladder cancer

Adjuvant / Neoadjuvant:

    Phase III, randomized, open-Label, multi-center, global study to determine the efficacy and safety of Durvalumab in combination With Gemcitabine+Cisplatin for neoadjuvant treatment followed by Durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer:


  • Javelin Bladder 100

    A phase 3, multicenter, multinational, randomised, open-label, parallel-arm study of Avelumab* (Msb0010718c) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy:

  • NILE
    A phase III, randomized, open-label, controlled, multi-center, global study of first-line Durvalumab in combination with standard of care chemotherapy and Durvalumab in combination with Tremelimumab and standard of care chemotherapy versus standard of care chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer:

Breast cancer

  • DESTINY-Breast 02
    A phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator's choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1:


    A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose) as treatment for heart failure with iron deficiency:


  • No trials currently recruiting

Gastrointestinal cancer



Germ cell cancer

  • P3BEP

    Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours:

Kidney cancer

    A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses:


  • Keynote 564

    A phase III, randomised, double-blind, placebo-controlled clinical trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (KEYNOTE-564):



    A multicenter, open-label, randomised, phase 3 trial to compare the efficacy and safety of Lenvatinib in combination with Everolimus or Pembrolizumab versus Sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma (CLEAR):


    A randomised, double-blind, placebo-controlled phase 2 study comparing CB-839 in combination with Cabozantinib (CB-Cabo) versus placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Multi-tumour trials

  • Javelin Medley

    A phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of Avelumab* (Msb0010718c) in combination with other cancer immunotherapies In patients with advanced malignancies:

  • Javelin PARP Medley

    A phase 1b/2 dose-finding and proof-of-concept (Poc) study to evaluate safety and anti-tumor activity of Avelumab in combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (Parp) inhibitor Talazoparib In patients with locally advanced or metastatic solid tumors:


Prostate cancer



  • IPATential 150

    A phase III, randomised, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, relative to placebo plus Abiraterone plus Prednisone/Prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer: 

  • JPCM
    Phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with metastatic castration-resistant prostate cancer:
    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer:


  • No trials currently recruiting

Content owner: Medicine and Health Sciences Last updated: 07 May 2019 11:09am

Back to the top of this page